Clinical Trial Update: Cetuximab Rechallenge in Irinotecan-pretreated mCRC, KRAS, NRAS and BRAF Wild-type Treated in 1st Line With Anti-EGFR Therapy (CRICKET). [Phase 2]

View source ↗

Summary

Phase 2 trial investigating cetuximab rechallenge in irinotecan-pretreated metastatic colorectal cancer with KRAS/NRAS/BRAF wild-type treated in first line with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Cetuximab (cetuximab)

Snippet

Sponsor: Gruppo Oncologico del Nord-Ovest | Conditions: Metastatic Colorectal Cancer | Phase 2 | Status: UNKNOWN